Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:4.6.1.1 (adenylate cyclase)
 19,190 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Convulxin (Cx), a component of the venom of the snake Crotalus durissus cascavella, induced the concentration-dependent aggregation of guinea-pig platelets when used at and above 50 +/- 5 ng/ml, accompanied by the release of ATP and by the formation of thromboxanes (Tx). Platelet activation by Cx was not due to potential contaminants found in the crude snake venom, such as phospholipase A2 and clotting enzymes. Aspirin (50-100 microM) failed to interfere with the platelet effects of Cx, demonstrating independence from cyclo-oxygenase. In contrast, indomethacin (50 microM) displayed a distinct inhibitory activity on the effects of Cx, as compared to aspirin, and thus exerts cyclo-oxygenase-independent effects on platelet activation. The ADP scavenger creatine phosphate/creatine phosphokinase (CP/CPK) inhibited aggregation by Cx used at concentrations below 6-8 times the threshold, but failed to interfere with higher amounts. Platelet aggregation by Cx was inhibited and reversed once established by EDTA (5mM) and by prostacyclin (0.1-1 microM). Cx-induced activation of platelets is thus Ca2+-dependent and liable to control by the adenylate cyclase-cyclic AMP system. Convulxin induced hypotension, bronchoconstriction and thrombocytopenia when injected i.v. to the anesthetised guinea pig at 0.3-3 microgram/kg. Aspirin and indomethacin (20 and 5 mg/kg respectively) mepyramine and methysergide (02. mg/kg) failed to interfere with these effects, but the combination of either aspirin or indomethacin with methysergide and mepyramine, suppressed the bronchial effects of Cx, leaving the hypotensive and thrombopenic effects unchanged. This synergism remains unexplained. Bronchoconstriction was platelet-dependent, being suppressed by platelet depletion with antiplatelet serum or by i.v. prostacyclin (1-10 microgram/kg).
 ...
PMID:Activation of guinea-pig platelets induced by convulxin, a substance extracted from the venom of Crotalus durissus cascavella. 700 69

It has been postulated that the main proaggregatory effect of thromboxane A2 (TxA2) is mediated by an inhibition of adenylate cyclase/cAMP complex, an effect similar to that of Na+ ion. The possibility of a modulation of the effect of Na+ on in vivo and in vitro platelet function of Dahl salt-sensitive (Dahl-S) and Dahl salt-resistant (Dahl-R) rats was investigated. Sulotroban, a powerful antagonist of prostaglandin peroxides and TxA2 was administered at doses of 1, 3 and 10 micrograms/kg/min. In vivo platelet activity was estimated on the basis of bleeding time and thrombocytopenia produced by i.v. bolus injection of 100 micrograms/kg collagen, and by plasma measurement of the stable prostacyclin and TxA2 analogs. In vitro aggregation was induced by collagen at concentrations of 10, 20, 30 and 40 micrograms/ml. Main blood pressure was measured directly in common carotid artery. The results showed that sulotroban did not produce hypotensive effects but did increase the bleeding time almost 2-fold. Plasma TxA2 levels were significantly increased in both Dahl-S and Dahl-R rats. The inhibition of collagen-induced aggregation and thrombocytopenia by sulotroban was negligible on Dahl-R rats but significant in Dahl-S rats. The results suggested a blocking effect of sulotroban not only on stimulus/receptor TxA2 complex but also on the inhibitory unit of adenylate cyclase complex, confirming this pathway of TxA2-induced aggregation.
 ...
PMID:Prostaglandin H2/thromboxane A2 pathway in platelet aggregation and activity of Dahl salt-sensitive rat--a sulotroban study. 881 65

The pituitary adenylate cyclase-activating polypeptide (PACAP) is a neuropeptide of the vasoactive intestinal peptide/secretin/glucagon superfamily. Studies in two related patients with a partial trisomy 18p revealed three copies of the PACAP gene and elevated PACAP concentrations in plasma. The patients suffer from severe mental retardation and have a bleeding tendency with mild thrombocytopenia, and their fibroblasts show increased PACAP mRNA levels. The PACAP receptor (vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor 1 [VPAC1]) in platelets and fibroblasts is coupled to adenylyl cyclase activation. Accordingly, we found increased basal cAMP levels in patients' platelets and fibroblasts, providing a basis for the reduced platelet aggregation in these patients. Megakaryocyte-specific transgenic overexpression of PACAP in mice correspondingly increased PACAP release from platelets, reduced platelet activation, and prolonged the tail bleeding time. In contrast, the PACAP antagonist PACAP(6-38) or a monoclonal PACAP antibody enhanced the collagen-induced aggregation of normal human platelets, and in PACAP knockout mice, an increased platelet sensitivity toward collagen was found. Thus, we found that PACAP modulates platelet function and demonstrated what we believe to be the first hemostatic defect associated with PACAP overexpression; our study suggests the therapeutic potential to manage arterial thrombosis or bleeding by administration of PACAP mimetics or inhibitors, respectively.
 ...
PMID:The pituitary adenylate cyclase-activating polypeptide is a physiological inhibitor of platelet activation. 1506 23